RXi Pharmaceuticals Corporation (NASDAQ:RXII) released its earnings results on Thursday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.11), MarketWatch Earnings reports. During the same period in the prior year, the firm posted ($0.34) EPS.

RXi Pharmaceuticals Corporation (NASDAQ RXII) traded up 0.655% during trading on Thursday, reaching $0.615. The company’s stock had a trading volume of 301,630 shares. The company’s market cap is $13.61 million. The stock’s 50-day moving average is $0.63 and its 200 day moving average is $0.66. RXi Pharmaceuticals Corporation has a 12 month low of $0.51 and a 12 month high of $2.93.

An institutional investor recently raised its position in RXi Pharmaceuticals Corporation stock. Renaissance Technologies LLC increased its stake in shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) by 26.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,980 shares of the biotechnology company’s stock after buying an additional 48,200 shares during the period. Renaissance Technologies LLC owned approximately 3.49% of RXi Pharmaceuticals Corporation worth $164,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.53% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by Daily Political and is the property of of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/10/rxi-pharmaceuticals-corporation-nasdaqrxii-issues-earnings-results.html.

RXi Pharmaceuticals Corporation Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Earnings History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.